A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.
Brown
J R
JR
Abramson
J
J
Hochberg
E
E
Mikler
E
E
Dalton
V
V
Werner
L
L
Reynolds
H
H
Thompson
C
C
McDonough
S M
SM
Kuang
Y
Y
Ritz
J
J
Neuberg
D
D
Freedman
A S
AS
D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001219:Aspartate Aminotransferases / Q000097:blood; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D000069283:Rituximab; D013921:Thrombocytopenia / Q000139:chemically induced; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives*
D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D014740:Vidarabine; C024352:fludarabine